
CI
USDThe Cigna Group Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$257.700
Kõrge
$264.800
Madal
$256.000
Maht
3.20M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
70.7B
Tööstusharu
Healthcare Plans
Riik
United States
Kauplemisstatistika
Keskmine maht
1.74M
Börs
NYQ
Valuuta
USD
52 nädala vahemik
Tehisintellekti analüüsiaruanne
Viimati uuendatud: 3. nov 2025Cigna (CI) Stock Analysis: Finding Opportunity in Recent Turmoil
What Happened to Cigna's Stock?
Cigna took a serious hit recently. On October 30th, shares plunged 18% to $247.10 on massive volume - nearly 5.5 times their average trading activity. The selling continued the next day, dropping the stock to $244.41. This puts CI dangerously close to its 52-week low of $240.67.
What's puzzling is this crash happened despite generally positive news. The company beat Q3 earnings estimates, Goldman Sachs just initiated coverage with a strong Buy rating and $370 price target (that's 50% above current levels), and they announced meaningful initiatives to reduce medication costs for Americans.
Reading Between the Price Lines
Let's unpack what's really happening with Cigna's chart:
- The Setup: Through most of August and September, CI built a solid upward trend, climbing from $260 to over $310
- The Breakdown: After peaking near $315, the stock drifted lower through October
- The Crash: That October 30th drop was no ordinary correction - it was a full-blown panic sell-off
Here's what stands out: the volume spike on October 30th wasn't normal distribution. When volume jumps that high during a sharp decline, it usually means big institutional players are exiting positions all at once. The good news? The selling pressure appears exhausted - the follow-through day on October 31st showed much weaker volume.
Why This Might Be Your Entry Window
Three compelling reasons suggest the worst may be over:
-
Technical Signals Flashing Green: The stock now sits right at its support level ($244.33). When prices bounce off support with conviction, it often marks a turning point. Right now, the distance between current price and support is practically nonexistent - meaning we're at the make-or-break point.
-
Goldman's Confidence: Their $370 price target isn't some random number. At current levels, that represents serious upside potential. What's interesting is they're not alone - 24 analysts maintain strong buy ratings.
-
The News/Price Disconnect: Positive earnings, strategic initiatives, and dividend stability shouldn't result in an 18% single-day drop. This mismatch creates what traders call "mispricing" - a temporary gap between actual value and market price
Seotud uudised
Analysts Lower Cigna Targets As PBM Segment Guidance Surprises Market
Cigna expects 2026–2027 margin pressure from its new rebate-free PBM model as major clients renew at lower margins, prompting analyst target cuts.
TD Cowen Maintains Buy on Cigna Group, Lowers Price Target to $333
TD Cowen analyst Charles Rhyee maintains Cigna Group with a Buy and lowers the price target from $387 to $333.
Goldman Sachs Maintains Buy on Cigna Group, Lowers Price Target to $330
Goldman Sachs analyst Scott Fidel maintains Cigna Group with a Buy and lowers the price target from $370 to $330.
JP Morgan Maintains Overweight on Cigna Group, Lowers Price Target to $375
JP Morgan analyst Lisa Gill maintains Cigna Group with a Overweight and lowers the price target from $428 to $375.
Barclays Maintains Overweight on Cigna Group, Lowers Price Target to $300
Barclays analyst Andrew Mok maintains Cigna Group with a Overweight and lowers the price target from $383 to $300.
Health insurer Cigna beats quarterly profit estimates on health services strength
Cigna Group beat Wall Street estimates for third-quarter profit on Thursday, driven by strength in the company's health services unit Evernorth that houses its pharmacy benefit management business.
Evernorth Announces New Era of Pharmacy Benefit Services to Lower Americans' Medication Costs
Evernorth, the health services division of The Cigna Group (NYSE:CI) today announced a new rebate-free pharmacy benefit model designed to help...
Tehisintellekti ennustusBeta
Tehisintellekti soovitus
Uuendatud kell: 5. nov 2025, 05:51
68.6% Kindlus
Risk ja kauplemine
Sisenemispunkt
$244.87
Võta kasum
$249.29
Peata kahjum
$219.96
Põhitegurid
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.